Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Meeting Abstract

    Moore, K. N.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Penkov, K.; Haanen, J. B. A. G.; Rini, B. I.; Albiges, L.; Campbell, M. T.; Kollmannsberger, C. K.; Negrier, S.; Uemura, M.; Lee, J. L.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950)
    Meeting Abstract

    Gounder, M.; Schöffski, P.; Villalobos, V.; Cote, G.; Chugh, R.; Chen, T. W. W.; Jahan, T.; Loggers, E. T.; Italiano, A.; Gupta, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinib
    Meeting Abstract

    George, S.; Bauer, S.; Jones, R. L.; Serrano, C.; von Mehren, M.; Kang, Y. K.; Schöffski, P.; Cassier, P.; Eskens, F. A.; Mir, O.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • VOYAGER: An open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)
    Meeting Abstract

    Bauer, S.; George, S.; Kang, Y. K.; Tap, W. D.; Zhou, T.; Picazio, N.; Boral, A. L.; Heinrich, M.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Overweight, obesity and weight gain after breast cancer (BC): A prospective clinical study
    Meeting Abstract

    Di Meglio, A.; El-Mouhebb, M.; Michiels, S.; Jones, L.; Annonay, M.; Zingarello, A.; Matias, M.; Everhard, S.; Martin, A. L.; Arveux, P.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors
    Meeting Abstract

    Tannir, N. M.; Naing, A.; Papadopoulos, K. P.; Wong, D. J.; Korn, W. M.; Aljumaily, R.; Autio, K. A.; Pant, S.; Bauer, T. M.; Drakaki, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors
    Meeting Abstract

    Garon, E. B.; Wong, D. J.; Schneider, J. G.; Aljumaily, R.; Korn, W. M.; Patel, M. R.; Autio, K. A.; Papadopoulos, K. P.; Naing, A.; Gabrail, N.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
    Meeting Abstract

    Solomon, B. J.; Martini, J. F.; Ou, S. H. I.; Chiari, R.; Soo, R. A.; Bearz, A.; Li, S.; Thurm, H.; Lin, C. C.; Riely, G. J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy and safety of crizotinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y)
    Meeting Abstract

    Moro-Sibilot, D.; Ahn, M. J.; Halmos, B.; Kim, D. W.; Riely, G. J.; Shaw, A. T.; Yang, P. C.; Lanzalone, S.; Polli, A.; Wilner, K. D.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save